Resources

Coulter Partners successfully completed a search assignment for Melt&Marble and is pleased to announce the placement of Tue Hodal as its first Chief Technology Officer (CTO).

Strategic partnership between Medicines Discovery Catapult and the Crick ensures continued national delivery of KQ Labs, a leading accelerator programme for early-stage innovators.

Aravax announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer.

Brainomix presented a series of new studies at the European Stroke Organisation Conference (ESOC) in Helsinki, solidifying the position of its market-leading Brainomix 360 Stroke as the most clinically validated stroke AI imaging solution.

Ikarovec has highlighted the therapeutic potential of its approach in geographic atrophy and wet AMD, with presentations at major ophthalmic and gene therapy conferences.

Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.

Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.

Brainomix Appoints Khush F. Mehta as chair to support global expansion and commercial growth.

Proprietary formulation technology is being applied to potentially enhance properties of nimacimab.

New studies presented at the American Thoracic Society (ATS) Conference this week validate e-Lung as an accurate tool to identify progressive pulmonary fibrosis.

Ferrer enters into a collaboration and license agreement with Prilenia for the commercialization and co-development of Pridopidine

AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open in the UK.

Vellos has announced a new partnership with Fifty Years. The partnership will support and inspire the next generation of entrepreneurs across the UK’s deep tech and life sciences sectors.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Dr. Stuart Hughes as Chief Executive Officer at Nuage Therapeutics S.L. (“Nuage”).

eXmoor Pharma has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub.

Cellestial Health, a pioneering pharmaceutical development spin-out from the University of Cambridge, has closed a £515,000 pre-seed equity funding round to accelerate the development of novel therapeutics targeting astrocytes, an often-overlooked cell type in the brain, with the first indication of Parkinson’s disease.

Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.

Coulter Partners successfully completed a search assignment for Tozaro and is pleased to announce the placement of Dr. Jason Slingsby, MBA as Chief Executive Officer.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.

Alchemab Therapeutics (Alchemab) today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.